Using powerful MRI to track iron levels in brain could be new way to monitor progression of MS

Public release date: 15-Dec-2011
[ | E-mail | Share ]

Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry

Medical researchers at the University of Alberta have discovered a new way to track the progression of multiple sclerosis (MS) in those living with the disease, by using a powerful, triple strength MRI to track increasing levels of iron found in brain tissue.

The researchers discovered that iron levels in MS patients are increasing in grey matter areas of the brain that are responsible for relaying messages. High iron levels in a specific "relay area" were noted in patients who had physical disabilities associated with MS. Iron is very important for normal function of the brain and the amount of iron is a tightly controlled system by the brain tissue. The discovery suggests there is a problem with the control system. Too much iron can be toxic to brain cells and high levels of iron in the brain have been associated with various neurodegenerative diseases. But to date, no tests have been able to quantify or measure iron in living brain.

Alan Wilman and Gregg Blevins, co-principal investigators from the Faculty of Medicine & Dentistry, used a new MRI method to quantitatively measure iron in the brain to gain a better understanding of what the disease is doing in the brains of those who were recently diagnosed with MS. Twenty-two people with MS took part in the study, along with 22 people who did not have the condition.

"In MS, there is a real desire and need to get a good idea of the state and progression of the disease," says Blevins, who is both a practising neurologist and a researcher from the Division of Neurology.

"When patients with MS currently get an MRI, the typical measures we look at may not give us a good idea of the nature and state of MS. Using this new MRI method would give physicians a new way to measure the effectiveness of new treatments for patients with MS by watching the impact on iron levels. This opens up the idea of having a new biomarker, a new way of looking at the disease over time, watching the disease, seeing the progression or lack of progression of the disease, a new way to track it."

Wilman, a researcher and physicist in the Department of Biomedical Engineering, says the new MRI method may be a better gauge for disease progression than strictly looking at number and frequency of relapses.

"This is a new quantitative marker that gives us more insight into MS. We can get a better handle on where patients are at. In terms of clinical symptoms, they may be fine for quite awhile, then they have a relapse, then they're fine for quite awhile. Well, the time when they are actually fine, they may not actually be alright.

"The disease may be progressing, but there is just no marker right now that shows that. We think the biomarker we have discovered could be an answer. People in the medical research community are very excited about this discovery, because it could be a new way of looking at the disease."

The new MRI method, which uses a machine that is 90,000 times the strength of the earth's magnetic field, will give physicians more detail and information about the impact of MS on the brain, insight that doctors and researchers didn't have before.

"This could be a very early marker of MS. We'd like to see this new method used with all patients who have MS. Ultimately, this discovery is a great example of translational research."

The researchers hope to see this new MRI method used in clinical trials for patients with MS within the next one to two years, then to be regularly used by physicians within five years.

Blevins and Wilman both credit the MS patients who took part in the study. "If patients weren't so willing to help, we couldn't do any of this," said Wilman.

###

*This discovery is not a confirmation of CCSVI because this discovery looks at iron existing in brain tissue, not iron from the blood.

The research study was funded by the Canadian Institutes of Health Research, the Natural Sciences and the Engineering Research Council of Canada, the Multiple Sclerosis Society of Canada and the University of Alberta Hospital Foundation.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 15-Dec-2011
[ | E-mail | Share ]

Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry

Medical researchers at the University of Alberta have discovered a new way to track the progression of multiple sclerosis (MS) in those living with the disease, by using a powerful, triple strength MRI to track increasing levels of iron found in brain tissue.

The researchers discovered that iron levels in MS patients are increasing in grey matter areas of the brain that are responsible for relaying messages. High iron levels in a specific "relay area" were noted in patients who had physical disabilities associated with MS. Iron is very important for normal function of the brain and the amount of iron is a tightly controlled system by the brain tissue. The discovery suggests there is a problem with the control system. Too much iron can be toxic to brain cells and high levels of iron in the brain have been associated with various neurodegenerative diseases. But to date, no tests have been able to quantify or measure iron in living brain.

Alan Wilman and Gregg Blevins, co-principal investigators from the Faculty of Medicine & Dentistry, used a new MRI method to quantitatively measure iron in the brain to gain a better understanding of what the disease is doing in the brains of those who were recently diagnosed with MS. Twenty-two people with MS took part in the study, along with 22 people who did not have the condition.

"In MS, there is a real desire and need to get a good idea of the state and progression of the disease," says Blevins, who is both a practising neurologist and a researcher from the Division of Neurology.

"When patients with MS currently get an MRI, the typical measures we look at may not give us a good idea of the nature and state of MS. Using this new MRI method would give physicians a new way to measure the effectiveness of new treatments for patients with MS by watching the impact on iron levels. This opens up the idea of having a new biomarker, a new way of looking at the disease over time, watching the disease, seeing the progression or lack of progression of the disease, a new way to track it."

Wilman, a researcher and physicist in the Department of Biomedical Engineering, says the new MRI method may be a better gauge for disease progression than strictly looking at number and frequency of relapses.

"This is a new quantitative marker that gives us more insight into MS. We can get a better handle on where patients are at. In terms of clinical symptoms, they may be fine for quite awhile, then they have a relapse, then they're fine for quite awhile. Well, the time when they are actually fine, they may not actually be alright.

"The disease may be progressing, but there is just no marker right now that shows that. We think the biomarker we have discovered could be an answer. People in the medical research community are very excited about this discovery, because it could be a new way of looking at the disease."

The new MRI method, which uses a machine that is 90,000 times the strength of the earth's magnetic field, will give physicians more detail and information about the impact of MS on the brain, insight that doctors and researchers didn't have before.

"This could be a very early marker of MS. We'd like to see this new method used with all patients who have MS. Ultimately, this discovery is a great example of translational research."

The researchers hope to see this new MRI method used in clinical trials for patients with MS within the next one to two years, then to be regularly used by physicians within five years.

Blevins and Wilman both credit the MS patients who took part in the study. "If patients weren't so willing to help, we couldn't do any of this," said Wilman.

###

*This discovery is not a confirmation of CCSVI because this discovery looks at iron existing in brain tissue, not iron from the blood.

The research study was funded by the Canadian Institutes of Health Research, the Natural Sciences and the Engineering Research Council of Canada, the Multiple Sclerosis Society of Canada and the University of Alberta Hospital Foundation.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2011-12/uoaf-upm121311.php

cain accuser aesop rock take care track list michael jackson trial carlos the jackal namibia namibia